v3.25.1
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
Total
Series G, Preferred Stocks
Class A Common Stock
Additional Paid-In Capital
Accumulated other comprehensive Income
Accumulated Deficit
Balance, shares at Jun. 30, 2023     37,344,739      
Balance, amount at Jun. 30, 2023 $ 35,952,525   $ 373,447 $ 242,808,771 $ 606,536 $ (207,836,229)
Employee Stock Purchase Plan, shares     14,607      
Employee Stock Purchase Plan, amount 19,719   $ 146 19,573    
Exercise of Stock Options, RSUs & RSAs, net, shares     14,482      
Exercise of Stock Options, RSUs & RSAs, net, amount     $ 145 (145)    
Issuance of common stock for acquisition of Visimid, shares     81,610      
Issuance of common stock for acquisition of Visimid, amount 150,000   $ 816 149,184    
Stock-based compensation on stock options, RSUs & RSAs 240,075     240,075    
Foreign currency translation adjustment (125,208)       (125,208)  
Net loss (1,342,376)         (1,342,376)
Balance, shares at Sep. 30, 2023     37,455,438      
Balance, amount at Sep. 30, 2023 34,894,735   $ 374,554 243,217,458 481,328 (209,178,605)
Balance, shares at Jun. 30, 2023     37,344,739      
Balance, amount at Jun. 30, 2023 35,952,525   $ 373,447 242,808,771 606,536 (207,836,229)
Foreign currency translation adjustment 22,409          
Net loss (5,653,573)          
Balance, shares at Mar. 31, 2024     38,126,249      
Balance, amount at Mar. 31, 2024 31,708,558   $ 381,262 244,188,153 628,945 (213,489,802)
Balance, shares at Sep. 30, 2023     37,455,438      
Balance, amount at Sep. 30, 2023 34,894,735   $ 374,554 243,217,458 481,328 (209,178,605)
Exercise of Stock Options, RSUs & RSAs, net, shares     93,940      
Exercise of Stock Options, RSUs & RSAs, net, amount     $ 940 (940)    
Stock-based compensation on stock options, RSUs & RSAs 258,691     258,691    
Foreign currency translation adjustment 259,973       259,973  
Net loss (1,713,663)         (1,713,663)
Balance, shares at Dec. 31, 2023     37,549,378      
Balance, amount at Dec. 31, 2023 33,699,736   $ 375,494 243,475,209 741,301 (210,892,268)
Employee Stock Purchase Plan, shares     15,840      
Employee Stock Purchase Plan, amount 19,958   $ 158 19,800    
Exercise of Stock Options, RSUs & RSAs, net, shares     225,814      
Exercise of Stock Options, RSUs & RSAs, net, amount     $ 2,258 (2,258)    
Issuance of common stock for acquisition of Visimid, shares     267,176      
Issuance of common stock for acquisition of Visimid, amount 336,054   $ 2,672 333,382    
Stock-based compensation on stock options, RSUs & RSAs 264,492     264,492    
Foreign currency translation adjustment (112,356)       (112,356)  
Net loss (2,597,534)         (2,597,534)
Issuance of common stock under public equity placement, shares     68,041      
Issuance of common stock under public equity placement, amount 98,208   $ 680 97,528    
Balance, shares at Mar. 31, 2024     38,126,249      
Balance, amount at Mar. 31, 2024 31,708,558   $ 381,262 244,188,153 628,945 (213,489,802)
Balance, shares at Jun. 30, 2024     39,254,643      
Balance, amount at Jun. 30, 2024 30,199,665   $ 392,546 245,140,758 509,936 (215,843,575)
Employee Stock Purchase Plan, shares     8,232      
Employee Stock Purchase Plan, amount 10,372   $ 82 10,290    
Stock-based compensation on stock options, RSUs & RSAs 264,475     264,475    
Foreign currency translation adjustment 271,594       271,594  
Net loss (1,622,745)         (1,622,745)
Exercise of Stock Options, RSUs & RSAs, net     703 (703)    
Issuance of common stock for acquisition of Visimid 321,358   $ 2,796 318,562    
Balance, shares at Sep. 30, 2024     39,612,737      
Balance, amount at Sep. 30, 2024 29,444,719   $ 396,127 245,733,382 781,530 (217,466,320)
Balance, shares at Jun. 30, 2024     39,254,643      
Balance, amount at Jun. 30, 2024 30,199,665   $ 392,546 245,140,758 509,936 (215,843,575)
Foreign currency translation adjustment (58,869)          
Net loss (7,817,202)          
Balance, shares at Mar. 31, 2025   255 42,893,563      
Balance, amount at Mar. 31, 2025 15,724,400 $ 34,399,622 $ 428,936 238,505,174 451,067 (223,660,777)
Balance, shares at Sep. 30, 2024     39,612,737      
Balance, amount at Sep. 30, 2024 29,444,719   $ 396,127 245,733,382 781,530 (217,466,320)
Stock-based compensation on stock options, RSUs & RSAs 231,581     231,581    
Foreign currency translation adjustment (451,035)       (451,035)  
Net loss (2,611,997)         (2,611,997)
Exercise of Stock Options, RSUs & RSAs, net     2,291 (2,291)    
Shares issued as compensation 89,670   $ 490 89,180    
Balance, shares at Dec. 31, 2024     39,890,834      
Balance, amount at Dec. 31, 2024 26,702,938   $ 398,908 246,051,852 330,495 (220,078,317)
Employee Stock Purchase Plan, shares     1,137      
Employee Stock Purchase Plan, amount 4,013   $ 11 4,002    
Exercise of Stock Options, RSUs & RSAs, net, amount 3,175   $ 2,387 788    
Issuance of common stock for acquisition of Visimid, shares     102,700      
Issuance of common stock for acquisition of Visimid, amount 392,588   $ 1,027 391,561    
Stock-based compensation on stock options, RSUs & RSAs 194,303     194,303    
Foreign currency translation adjustment 120,572       120,572  
Net loss (3,582,460)         (3,582,460)
Issuance of common stock under public equity placement, shares     687,750      
Issuance of preferred stock under private equity placement, net of fees, shares   255        
Issuance of preferred stock under private equity placement, net of fees, amount 0 $ 19,648,488   0    
Exercise of Stock Options, RSUs & RSAs, net, shares     238,641      
Issuance of warrants under private placement, net of fees 177,445     177,445    
Issuance of common stock for acquisition of G5, shares     1,972,501      
Issuance of common stock for acquisition of G5, amount 4,872,068   $ 19,725 4,852,343    
Issuance of common stock under private equity placement, net of fees, amount 1,590,892   $ 6,878 1,584,014    
Preferred cumulative dividend plus accretion (14,751,134) $ 14,751,134   (14,751,134)    
Balance, shares at Mar. 31, 2025   255 42,893,563      
Balance, amount at Mar. 31, 2025 $ 15,724,400 $ 34,399,622 $ 428,936 $ 238,505,174 $ 451,067 $ (223,660,777)